1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

Lipum: A new approach to chronic inflammation

• Addressing a large patient group in need of new treatment alternatives
• Phase I to be concluded in 2024
• We initiate coverage with a fair value of SEK 10.81 per share

Chronic inflammation, such as rheumatoid arthritis, affects millions of people globally. Available treatment options are often insufficient and new approaches are much needed. Umeå-based Lipum develops SOL-116, a new way to treat inflammation. The company expects to conclude the phase I study by late 2024 and plans for the next development step.

Västra Hamnen initiates research coverage of Lipum with a fair value of SEK 10.81 per share. The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://twitter.com/vhcorp_se)

Datum 2024-05-29, kl 10:45
Källa MFN
Affiliate
Kopiera toppinvesterare! Med eToros innovativa CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för att använda CopyTrader-funktionen.
Copy Trading innebär inte investeringsråd. Värdet på dina investeringar kan gå upp eller ned. Ditt kapital löper risk.